## Shubhabrata Mukherjee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8388705/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
2	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
3	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
4	Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging and Behavior, 2012, 6, 502-516.	1.1	443
5	A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging and Behavior, 2012, 6, 517-527.	1.1	371
6	A statistical framework for cross-tissue transcriptome-wide association analysis. Nature Genetics, 2019, 51, 568-576.	9.4	262
7	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	4.1	260
8	Alzheimer's Disease: Analyzing the Missing Heritability. PLoS ONE, 2013, 8, e79771.	1.1	257
9	Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurology, 2018, 75, 989.	4.5	223
10	Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiology of Aging, 2016, 41, 200.e13-200.e20.	1.5	174
11	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.4	166
12	Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study. PLoS Medicine, 2015, 12, e1001841.	3.9	153
13	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	4.5	144
14	A Powerful Approach to Estimating Annotation-Stratified Genetic Covariance via GWAS Summary Statistics. American Journal of Human Genetics, 2017, 101, 939-964.	2.6	141
15	Imputation and quality control steps for combining multiple genome-wide datasets. Frontiers in Genetics, 2014, 5, 370.	1.1	130
16	Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels. Alzheimer's Research and Therapy, 2014, 6, 39.	3.0	106
17	Normal-Based Methods for a Gamma Distribution. Technometrics, 2008, 50, 69-78.	1.3	102
18	Effects of education and race on cognitive decline: An integrative study of generalizability versus study-specific results Psychology and Aging, 2015, 30, 863-880.	1.4	100

#	Article	IF	CITATIONS
19	Harmonizing Clinical Sequencing and Interpretation for the eMERGE III Network. American Journal of Human Genetics, 2019, 105, 588-605.	2.6	99
20	Neuropathological and transcriptomic characteristics of the aged brain. ELife, 2017, 6, .	2.8	97
21	Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimer's disease. PLoS Genetics, 2017, 13, e1006933.	1.5	96
22	Genetic variants and functional pathways associated with resilience to Alzheimer's disease. Brain, 2020, 143, 2561-2575.	3.7	93
23	Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathologica, 2018, 136, 857-872.	3.9	87
24	Inference on Reliability in Two-parameter Exponential Stress–strength Model. Metrika, 2007, 65, 261-273.	0.5	79
25	Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 53, 921-932.	1.2	77
26	Local ancestry at <i>APOE</i> modifies Alzheimer's disease risk in Caribbean Hispanics. Alzheimer's and Dementia, 2019, 15, 1524-1532.	0.4	75
27	Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia. Human Molecular Genetics, 2015, 24, 3557-3570.	1.4	69
28	Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A case–control study. PLoS Medicine, 2017, 14, e1002272.	3.9	67
29	Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease. Brain Imaging and Behavior, 2012, 6, 551-567.	1.1	66
30	Sex differences in the genetic predictors of Alzheimer's pathology. Brain, 2019, 142, 2581-2589.	3.7	65
31	Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging and Behavior, 2012, 6, 634-648.	1.1	58
32	Analysis pipeline for the epistasis search ââ,¬â€œ statistical versus biological filtering. Frontiers in Genetics, 2014, 5, 106.	1.1	57
33	Genetic data and cognitively defined late-onset Alzheimer's disease subgroups. Molecular Psychiatry, 2020, 25, 2942-2951.	4.1	57
34	Genetic-based prediction of disease traits: prediction is very difficult, especially about the futureââ,¬Â. Frontiers in Genetics, 2014, 5, 162.	1.1	53
35	Incidence of cognitively defined lateâ€onset Alzheimer's dementia subgroups from a prospective cohort study. Alzheimer's and Dementia, 2017, 13, 1307-1316.	0.4	49
36	Explaining Differences in Episodic Memory Performance among Older African Americans and Whites: The Roles of Factors Related to Cognitive Reserve and Test Bias. Journal of the International Neuropsychological Society, 2011, 17, 625-638.	1.2	48

#	Article	IF	CITATIONS
37	Relationship between baseline brain metabolism measured using [18F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging and Behavior, 2012, 6, 568-583.	1.1	47
38	Genetically predicted body mass index and Alzheimer's disease–related phenotypes in three large samples: Mendelian randomization analyses. Alzheimer's and Dementia, 2015, 11, 1439-1451.	0.4	46
39	Calibrating Longitudinal Cognition in Alzheimer's Disease Across Diverse Test Batteries and Datasets. Neuroepidemiology, 2014, 43, 194-205.	1.1	43
40	Systems biology approach to late-onset Alzheimer's disease genome-wide association study identifies novel candidate genes validated using brain expression data and Caenorhabditis elegans experiments. , 2017, 13, 1133-1142.		40
41	Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiology of Aging, 2016, 38, 141-150.	1.5	39
42	Gene-based GWAS and biological pathway analysis of the resilience of executive functioning. Brain Imaging and Behavior, 2014, 8, 110-118.	1.1	33
43	Transcriptomic stratification of late-onset Alzheimer's cases reveals novel genetic modifiers of disease pathology. PLoS Genetics, 2020, 16, e1008775.	1.5	31
44	Distinct clinicopathologic clusters of persons with TDP-43 proteinopathy. Acta Neuropathologica, 2020, 140, 659-674.	3.9	29
45	Development and validation of language and visuospatial composite scores in ADNI. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12072.	1.8	29
46	Genomeâ€wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways. Alzheimer's and Dementia, 2020, 16, 1134-1145.	0.4	28
47	Diabetic Phenotypes and Late-Life Dementia Risk. Alzheimer Disease and Associated Disorders, 2016, 30, 15-20.	0.6	27
48	Analysis of genes (TMEM106B, GRN, ABCC9, KCNMB2, and APOE) implicated in risk for LATE-NC and hippocampal sclerosis provides pathogenetic insights: a retrospective genetic association study. Acta Neuropathologica Communications, 2021, 9, 152.	2.4	26
49	Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease. Brain, 2022, 145, 2541-2554.	3.7	26
50	Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes. Neurobiology of Aging, 2015, 36, 2501-2508.	1.5	23
51	Genetic architecture of resilience of executive functioning. Brain Imaging and Behavior, 2012, 6, 621-633.	1.1	22
52	<i>MAPT</i> haplotype–stratified GWAS reveals differential association for AD risk variants. Alzheimer's and Dementia, 2020, 16, 983-1002.	0.4	21
53	You Say Tomato, I Say Radish: Can Brief Cognitive Assessments in the U.S. Health Retirement Study Be Harmonized With Its International Partner Studies?. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2021, 76, 1767-1776.	2.4	21
54	Interaction between variants in <i>CLU</i> and <i>MS4A4E</i> modulates Alzheimer's disease risk. Alzheimer's and Dementia, 2016, 12, 121-129.	0.4	18

#	Article	IF	CITATIONS
55	Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI. Brain Imaging and Behavior, 2012, 6, 649-660.	1.1	16
56	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. NeuroImage: Clinical, 2021, 30, 102660.	1.4	13
57	Differential item functioning due to cognitive status does not impact depressive symptom measures in four heterogeneous samples of older adults. International Journal of Geriatric Psychiatry, 2015, 30, 911-918.	1.3	11
58	The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable. Neurobiology of Aging, 2016, 41, 115-121.	1.5	11
59	Failure to detect synergy between variants in transferrin and hemochromatosis and Alzheimer's disease in large cohort. Neurobiology of Aging, 2020, 89, 142.e9-142.e12.	1.5	9
60	Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups. NeuroImage: Clinical, 2021, 31, 102725.	1.4	9
61	Alzheimer's disease genetic risk variants beyond APOE Îμ4 predict mortality. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 188-195.	1.2	8
62	Modern psychometric methods for estimating physician performance on the Clinician and Group CAHPS® survey. Health Services and Outcomes Research Methodology, 2013, 13, 109-123.	0.8	7
63	Demographic characteristics do not decrease the utility of depressive symptoms assessments: examining the practical impact of item bias in four heterogeneous samples of older adults. International Journal of Geriatric Psychiatry, 2015, 30, 88-96.	1.3	7
64	Associations Between Depression, Traumatic Brain Injury, and Cognitively-Defined Late-Onset Alzheimer's Disease Subgroups. Journal of Alzheimer's Disease, 2019, 70, 611-619.	1.2	7
65	Longitudinal cognitive performance of Alzheimer's disease neuropathological subtypes. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12201.	1.8	7
66	Association between WWOX/MAF variants and dementia-related neuropathologic endophenotypes. Neurobiology of Aging, 2022, 111, 95-106.	1.5	6
67	A SYSTEMS-BIOLOGY APPROACH TO IDENTIFY CANDIDATE GENES FOR ALZHEIMER'S DISEASE BY INTEGRATING PROTEIN-PROTEIN INTERACTION NETWORK AND SUBSEQUENT IN VIVO VALIDATION OF CANDIDATE GENES USING A C. ELEGANS MODEL OF AB TOXICITY. , 2014, 10, P298-P299.		4
68	P3-002: GWAS of the joint ADGC data set identifies novel common variants associated with late-onset Alzheimer's disease. , 2013, 9, P550-P550.		2
69	Predictive analysis of engine health for decision support. SIGKDD Explorations: Newsletter of the Special Interest Group (SIG) on Knowledge Discovery & Data Mining, 2014, 15, 39-49.	3.2	2
70	Impact of home visit capacity on genetic association studies of late-onset Alzheimer's disease. , 2017, 13, 933-939.		2
71	Harmonizing the preclinical Alzheimer cognitive composite for multiâ€cohort studies. Alzheimer's and Dementia, 2020, 16, e047423.	0.4	2
72	Genome-wide association study of brain arteriolosclerosis. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 1437-1450.	2.4	2

#	Article	IF	CITATIONS
73	P3-316: CALIBRATING LONGITUDINAL COGNITIVE PERFORMANCE ACROSS DIVERSE NEUROPSYCHOLOGICAL BATTERIES AND DATASETS. , 2014, 10, P746-P746.		1
74	P1-045: EXOME ARRAY ANALYSIS IDENTIFIES NOVEL RISK VARIANTS FOR ALZHEIMER'S DISEASE WITH ONSET BEFORE 65 YEARS. , 2014, 10, P319-P319.		1
75	P2â€076: Alzheimer's Disease Genetic Risk Variants Beyond <i>Apoe</i> ε4 Predict Mortality in The Adult Changes in Thought (ACT) Study. Alzheimer's and Dementia, 2016, 12, P637.	0.4	1
76	[P2–118]: FINEâ€MAPPING OF THE HUMAN LEUKOCYTE ANTIGEN (HLA) LOCUS AS A RISK FACTOR FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P652.	0.4	1
77	Sixâ€month decline in language, but not other cognitive domains, identifies increased risk of conversion from MCI to AD in ADNI. Alzheimer's and Dementia, 2020, 16, e045357.	0.4	1
78	O4-04-02: A NOVEL SUSCEPTIBILITY LOCUS FOR NEUROFIBRILLARY TANGLES AT PTPRD: EVIDENCE OF PLEIOTROPIC EFFECTS ON OTHER BRAIN PATHOLOGIES. , 2014, 10, P256-P257.		0
79	P1-038: GENOME-WIDE ANALYSIS OF AMYLOID BETA (AB) PEPTIDE OBTAINED FROM HISTELIDE IDENTIFIES SUGGESTIVE HITS IN RHBDF1, GRID1, AND PTPRD REGIONS IN THE ADULT CHANGES IN THOUGHT (ACT) STUDY. , 2014, 10, P317-P317.		0
80	P4-010: Genome-wide association study of the robust aging in adult changes of thought (ACT). , 2015, 11, P769-P769.		0
81	P2-016: Identification of genetic variants associated with Alzheimer's disease: Progression rate. , 2015, 11, P487-P487.		0
82	O4-12-01: Integrating human protein-protein interaction network with results from gwas in whites and african-americans identifies common genes underlying late-onset Alzheimer's disease. , 2015, 11, P299-P299.		0
83	O1-03-01: Integrative Analysis of Gwas Summary Data and Functional Annotations Highlights Signal Enrichment in Immune-Related DNA Elements for Late-Onset Alzheimer's Disease. , 2016, 12, P176-P177.		Ο
84	P1â€387: Incidence of Dementia Subtypes in a Communityâ€Based Prospective Cohort Study: The Adult Changes in Thought (ACT) Study. Alzheimer's and Dementia, 2016, 12, P580.	0.4	0
85	P2â€089: Impact of Home Visit Capacity on Genetic Association Studies of Lateâ€Onset Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P643.	0.4	0
86	P3â€082: Assessment of the Genetic Variance of Lateâ€Onset Alzheimer's Disease. Alzheimer's and Dementia 2016, 12, P849.	'0.4	0
87	P3â€090: Integrative Analysis of GWAS Summary Data and Functional Annotations Identifies Additional Loci for Lateâ€Onset Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P854.	0.4	0
88	P3â€096: Secondary Analyses of International Genomics of Alzheimer's Project Stage I GWAS Summary Data Identifies Additional Variants Associated With Lateâ€Onset Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P856.	0.4	0
89	[P1–245]: HETEROGENEITY OF RISK ACROSS NONâ€VASCULAR RISK FACTORS FOR SPECIFIC COGNITIVELYâ€DEFINED ALZHEIMER'S DISEASE SUBGROUPS. Alzheimer's and Dementia, 2017, 13, P339.	0.4	0
90	[P2–437]: DECLINE IN EPISODIC MEMORY ASSOCIATED WITH GREATER RISK OF MIXED NEUROPATHOLOGY COMPARED TO PURE ALZHEIMER'S PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P803.	0.4	0

#	Article	IF	CITATIONS
91	[O1–O3–O5]: ANNOTATIONâ€STRATIFIED GENETIC CORRELATION ANALYSIS IDENTIFIES SHARED AND DISTIN GENETIC ARCHITECTURE OF LATEâ€ONSET ALZHEIMER's DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS. Alzheimer's and Dementia, 2017, 13, P193.	CT 0.4	0
92	[P4–410]: PSYCHOMETRICALLYâ€DEFINED LATEâ€ONSET ALZHEIMER'S DISEASE (LOAD) SUBGROUPS IN 5 STL (TOTAL N = 4,170): PREVALENCE AT FIRST VISIT, ASSOCIATIONS WITH APOE GENOTYPE AND IGAP SNPS, AND GWAS. Alzheimer's and Dementia, 2017, 13, P1488.	IDIES 0.4	0
93	[P1–582]: DIFFERENTIAL VASCULAR RISK FACTORS FOR COGNITIVELY DEFINED ALZHEIMER's DISEASE SUBGROUPS. Alzheimer's and Dementia, 2017, 13, P517.	0.4	0
94	O3â€03â€06: CROSSâ€TISSUE TRANSCRIPTOMEâ€WIDE ASSOCIATION METAâ€ANALYSIS IDENTIFIES NOVEL RIS FOR LATEâ€ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1017.	K GENES	0
95	P2â€141: CHR17Q21 H2 HAPLOTYPE STRATIFIED GWAS REVEALS DIFFERENTIAL ASSOCIATION FOR AD RISK VARIANTS. Alzheimer's and Dementia, 2018, 14, P722.	0.4	0
96	P1â€139: THE CONTRIBUTION OF SEXâ€SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P327.	0.4	0
97	P1â€493: CLINICAL VERSUS NEUROPATHOLOGICAL DIAGNOSIS IN ALZHEIMER'S DISEASE RESEARCH. Alzheimer's and Dementia, 2018, 14, P517.	0.4	0
98	P2â€104: SYNERGY BETWEEN RS1049296 IN TRANSFERRIN AND RS1800562 IN HEMOCHROMATOSIS AS A RISK FACTOR FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P708.	0.4	0
99	P1â€141: GENOMEâ€WIDE ANALYSES OF ISOLATED RELATIVE COGNITIVE IMPAIRMENTS IDENTIFIES SUGGESTIVE HITS IN FIVE STUDIES. Alzheimer's and Dementia, 2018, 14, P329.	0.4	0
100	P3â€483: COGNITIVELY DEFINED LOAD SUBGROUPS ARE CHARACTERIZED BY HETEROGENEOUS PATTERNS OF RELATIVE DEFICITS IN THE FIVE YEARS PRECEDING LOAD DIAGNOSIS. Alzheimer's and Dementia, 2018, 14, P1306.	0.4	0
101	P4â€494: GENETIC ARCHITECTURE OF RELATIVE MEMORY PERFORMANCE AMONG PEOPLE WITH ALZHEIMER'S DISEASE DIFFERS BY <i>APOE</i> GENOTYPE ACROSS FIVE COHORTS. Alzheimer's and Dementia, 2019, 15, P1502.	0.4	0
102	ICâ€Pâ€076: FDGâ€PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELYâ€DEFINED SUBGRO ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P68.	UPS OF	0
103	Sex differences in genetic predictors of resilience to Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e043259.	0.4	0
104	Genomeâ€wide association analysis of neurofibrillary tangle burden identifies novel risk loci in the adult changes of thought (ACT) and the religious orders study and memory and aging project (ROSMAP) autopsy cohorts. Alzheimer's and Dementia, 2020, 16, e043573.	0.4	0
105	Development and validation of composite scores for language and visuospatial functioning in ADNI. Alzheimer's and Dementia, 2020, 16, e045508.	0.4	0
106	Proteinâ€protein interaction networks of genes associated with different cognitively defined subtypes of lateâ€onset Alzheimer's disease in five white populations identify novel candidate genes. Alzheimer's and Dementia, 2020, 16, e045014.	0.4	0
107	The Group Health-University of Washington Adult Changes in Thought Study: A Living, Learning Laboratory for Aging and Multiple Chronic Conditions Research. Journal of Patient-centered Research and Reviews, 2015, 2, 107.	0.6	0